1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The intent of the FY20 PRARP ADTBI is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for chronic TBI as they pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice. The FY20 PRARP ADTBI mechanism defines biomarker qualification as the evidentiary process of linking a biomarker with biological processes and clinical end points. Applications may consider elements of biomarker validation as part of the application. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Applications that detail biomarker validation work should demonstrate how this research is relevant to overall biomarker qualification. As part of the application, the proposed biomarkers should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of chronic TBI as it pertains to AD/ADRD as the study endpoint. The FY20 PRARP ADTBI does not support basic discovery of biomarkers. As such, animal research is prohibited. The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to both TBI and AD/ADRD research. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. The FY20 PRARP ADTBI encourages applications to consider fluid-based, imaging-based, retinal or wearable devices as potential diagnostics. Demonstration of access to an already existing cohort or provision of a plan that demonstrates expedited participant accrual is required. In addition, suitability of the existing cohort or participant population must be detailed. Applications must therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. FY20 PRARP ADTBI applications must be Impact-based.
Funding Opportunity Number: W81XWH-20-PRARP-ADTBI. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $15M total program funding.
Get alerted about grants like this
Get emailed when new opportunities from “Dept. of the Army -- USAMRAA” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $15M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was July 21, 2020, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Yes — DoD Peer Reviewed Alzheimer’s, Accelerating Diagnostics for Traumatic Brain Injury Research Award is offered by Dept. of the Army -- USAMRAA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award, a product-driven award mechanism, intends to support the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines. Products in development should address or have dual purpose potential for the health care needs of military Service Members, Veterans and their Families.Distinctive Features: For the PRMRP Technology/Therapeutic Development Award, the program expects the research proposed will take an already established proof-of-concept or prototype through the final stages of preclinical development. The PRMRP also expects that the research outcome will be a regulatory filing or translation of findings into clinical practice, as applicable.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $67.2M to fund approximately 12 Technology/Therapeutic Development Award applications with total cost caps of $5.6M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027. Funding Opportunity Number: HT942526PRMRPTTDA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $67.2M total program funding.
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Lifestyle and Applied Health Research Award supports clinical research and/or clinical trials using a combination of scientific disciplines including occupational science, psychology, psychometrics, biostatistics and epidemiology, surveillance, implementation science, and population health. Applications must address and provide a solution to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals.Distinctive Features: This funding opportunity requires patient advocate participation. The patient advocate will be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas. Animal research is not allowed.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $16.8M to fund approximately four Lifestyle and Applied Health Research Award applications with total cost caps of $4.2M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027. Funding Opportunity Number: HT942526PRMRPLAHRA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $16.8M total program funding.
Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award is sponsored by Department of Defense (DOD) / Congressionally Directed Medical Research Programs (CDMRP). This award supports the translation of promising preclinical findings into products for clinical applications (prevention, detection, diagnosis, treatment, or quality of life) for diseases or conditions related to the FY26 PRMRP topic areas and strategic goals. Products can be tangible items or knowledge products. The program expects research to take an established proof-of-concept or prototype through final preclinical development, aiming for regulatory filing or translation into clinical practice. Products should also address the healthcare needs of military Service Members, Veterans, and their Families.
Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award is sponsored by Department of Defense (DoD) - Congressionally Directed Medical Research Programs (CDMRP). This award supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for diseases relevant to military Service Members, Veterans, and their Families.
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article